Introduction
============

During an episode of critical illness a number of significant changes occur in the microbiota of the human gut. These changes occur due to alterations in the stress hormone profile, impairment of blood supply to the gut, immunosuppression, antibiotic use and nutrient deficiency \[[@B1]\]. In experimental models these changes have been shown to occur within 6 to 8 hours, with endogenous *Lactobacillus*strains being replaced by pathogenic bacteria \[[@B2]\]. This change can lead to a breakdown in the intestinal barrier function that is likely to play a significant role in the pathogenesis of multiple organ dysfunction syndrome \[[@B3],[@B4]\].

Redressing this balance and exploiting the beneficial effects of probiotic bacteria is understandably an area of considerable interest. However, the mechanisms by which these microorganisms exert their effects are various and depend upon the dose used, the route(s) of administration and the dosing frequency \[[@B5]\]. Furthermore, a number of these effects are strain specific.

Probiotics, prebiotics and synbiotics
=====================================

Probiotics are defined as \'live microorganisms that confer a health benefit on the host when administered in adequate amounts\' \[[@B6]\]. Prebiotics are nondigestible food components that stimulate the growth and/or activity of bacteria in the digestive tract in ways that may be beneficial to health \[[@B7]\]. Synbiotics are a combination of probiotics and prebiotics. There has been an explosion of interest in probiotics and their potential health benefits since 2000, with initial attention focusing on the gastrointestinal tract.

Probiotics and the gastrointestinal tract
=========================================

The human intestine is home to hundreds of species of bacteria, archaea and eukarya, many of which are non-culturable but can now be identified using metagenomic approaches. The bacterial load tends to be highest in the large intestine (up to 10^11^colony-forming units/g), and while the healthy human gut is dominated by *Bacteroides*, *Firmicutes*and *Actinobacteria*, each individual has their own distinct stool bacterial composition determined by environmental and genetic factors. This bacterial profile remains relatively constant over time unless altered by disease state or antibacterial treatment \[[@B8],[@B9]\].

Culture-based and molecular detection methods have demonstrated that it is possible to significantly alter the composition of gut flora in adults and infants by treatment with probiotics. Sepp and colleagues treated 15 neonates with *Lactobacillus rhamnosus*GG for the first 2 weeks of life. They found that *L. rhamnosus*GG persisted for 1 month in eight of these neonates. There were also significant differences in the bacterial composition of the stool compared with the control group, with increased numbers of coliforms, lactobacilli and *Bifido-bacterium*spp. \[[@B10]\]. Benno and colleagues demonstrated a statistically significant increase in bifidobacteria in adults treated with *L. rhamnosus*GG for a 4-week period. They also found an increase in lactobacilli and a decrease in the proportion of *Clostridium*spp. \[[@B11]\]. As these techniques are based on faecal profiling, they tend to reflect the large bowel bacterial composition with little information being available on the small bowel effects of probiotics.

Mechanisms of action of probiotics
==================================

Much of the information available on the mechanisms of action of probiotics is obtained from animal work and *in vitro*studies; hence we must be careful in extrapolating this to humans. What is clear, however, is that there are multiple mechanisms by which different probiotic bacteria exert their effects, and these effects may vary with the strain and population studied. Table [1](#T1){ref-type="table"} summarises the main mechanisms by which probiotics exert their effects, and Table [2](#T2){ref-type="table"} presents details of commonly used probiotic preparations.

###### 

Summary of mechanisms of action for probiotics

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Mechanism of action                                                                                                                                                                                                                                                                                            Specific probiotic examples
  -------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Luminal pH modification                      Production of lactic acid and acetic acid reduces luminal pH resulting in unfavourable milieu for pathogens                                                                                                                                                       *Lactobacillus*spp.: pH-dependent reduction in pathogen growth \[[@B12]\]\
                                                                                                                                                                                                                                                                                                                 VSL\#3: *in vivo*luminal pH reduction in ulcerative colitis patients \[[@B13]\]

  Bacteriocin production                       Bacteriocins are proteins produced by bacteria that inhibit the growth and virulence of other microorganisms. The may be narrow spectrum (inhibit related bacterial strains) or broad spectrum (inhibit a wide range of bacteria, yeasts and moulds) \[[@B15]\]   Mutant *Lactobacillus salivarius*deficient in bacteriocin gene are unable to protect mice against *Listeria monocytogenes*infection \[[@B14]\]\
                                                                                                                                                                                                                                                                                                                 *L. salivarius*subspecies produce broad-spectrum bacteriocins \[[@B16]\]

  Disruption of interbacterial communication   Autoinducers are the signalling molecules produced and secreted by bacteria that form the basis of quorum sensing (bacterial communication)                                                                                                                       *Lactobacillus acidophilus*La-5 disrupts quorum sensing and expression of virulence-related genes by *Escherichia coli*O157:H7 \[[@B17]\]

  Enhanced mucosal barrier function            Increased intestinal epithelial cell mucus production and secretion                                                                                                                                                                                               *Lactobacillus plantarum*299v: increased mucin gene expression *in vitro*\[[@B18]\] and adherence to colonic cells via a mannose-specific adherence mechanism \[[@B74]\]

                                               Reduced adhesion and invasion of intestinal epithelial cells by enteroinvasive bacteria resulting in reduced translocation                                                                                                                                        *Lactobacillus casei rhamnosus*adheres to colonic cells *in vitro*\[[@B75]\]

                                               Increased production of human β-defensin 2 by epithelial cells                                                                                                                                                                                                    *E. coli*Nissle 1917: increase in mucin gene expression \[[@B76]\] and production of human β-defensin 2 by colonic cells \[[@B77]\]

                                               Stabilisation of intracellular tight junctions and reduced chloride/water secretion                                                                                                                                                                               *Streptococcus thermophiles*and *L. acidophilus*reduce water and chloride secretion in response to pathogenic bacteria \[[@B78],[@B79]\]

                                               Epithelial cell regeneration and reduced apoptosis                                                                                                                                                                                                                *Lactobacillus*pretreatment of intestinal epithelium reduces disruption of epithelial tight junctions by pathogenic *E. coli*\[[@B80]\]. Probiotic preparation VSL\#3 (see Table 2) prevents redistribution of epithelial tight junction proteins on exposure to pathogenic bacteria \[[@B76]\]. *Lactobacillus rhamnosus*GG prevents cytokine-mediated apoptosis of intestinal epithelial cells \[[@B81]\]. *Lactobacillus casei*and *Clostridium butyricum*both stimulate gut epithelial proliferation in rats \[[@B82]\]

  Colonisation resistance                      The probiotic competes with pathogen for nutrients and adhesion in a microbiological niche \[[@B5]\]                                                                                                                                                              *L. casei rhamnosus*adheres to colonic cells, reduces pathogenic bacterial growth and can persist within the gastrointestinal tract \[[@B75],[@B83]\]

                                                                                                                                                                                                                                                                                                                 *E. coli*Nissle 1917 inhibits growth of Shiga-toxin producing *E. coli*\[[@B84]\]

  Immunological effects                        Bacterial-epithelial cross-talk enables luminal probiotic organisms to influence gut-associated lymphoid tissue and innate and adaptive host responses \[[@B19],[@B85]\]. Toll-like receptors play a central role in mediating this process \[[@B86]\]            VSL\#3 has been associated with increased anti-inflammatory and reduced proinflammatory cytokine activity, reduced inducible nitric oxide synthase and matrix metalloproteinase activity in patients with pouchitis \[[@B87]\]. *L. plantarum*299v increases IL-10 secretion from macrophages and T cells in patients with ulcerative colitis \[[@B88]\]. *L. casei*and *Lactobacillus bulgaricus*significantly reduce TNF*α*release from inflamed mucosa in Crohn\'s disease \[[@B89]\]. *E. coli*Nissle 1917 shows local and systemic anti-inflammatory effects in a murine model of lipopolysaccharide-induced sepsis \[[@B90]\]

                                               Increased promotion of B cells to plasma cells and increased production of immunoglobulins \[[@B5]\]                                                                                                                                                              *L. rhamnosus GG*: increased circulating IgA, IgG and IgM concentrations in children with gastroenteritis \[[@B91],[@B92]\]. Pretreatment with probiotic prior to typhoid vaccination leads to increased anti-typhoid antibody titres \[[@B93]\]

                                               Activation and modulation of macrophages, T cells and natural killer cells                                                                                                                                                                                        *L. casei*Shirota: cell wall structure potently induces IL-12 production and the probiotic differentially controls the inflammatory cytokine responses of macrophages, T cells and natural killer cells \[[@B30],[@B94],[@B95]\]. *L. casei*Shirota and *Bifidobacterium breve*administered preoperatively to biliary cancer patients significantly reduce postoperative IL-6, C-reactive protein and white cell count concentrations \[[@B30]\]. *L. acidophilus*and *Bifidobacterium longum*increased macrophage phagocytic activity in a murine model \[[@B96]\]
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Summary of probiotic preparations

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Probiotic                                                                   Constituents                                                                                                                                                                                                                                                                              Administration example and dosing comments
  --------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Antibiophilus (Lcr35) (Germania Pharmazeutika GesmbH, Vienna, Austria)      *Lactobacillus casei rhamnosus*                                                                                                                                                                                                                                                           10^9^CFU twice daily via nasogastric tube \[[@B75]\]

  Ecologic 641 (Winclove Bio Industries, Amsterdam, the Netherlands)          Six different strains of bacteria: *Lactobacillus acidophilus*, *Lactobacillus casei*, *actobacillus salivarius*, *Lactococcus lactis*, *Bifidobacterium bifidum*, and *Bifidobacterium lactis*(previously classified as *Bifidobacterium infantis*), plus cornstarch and maltodextrins   Administered twice daily via nasojejunal tube to a total daily dose of 10^10^bacteria \[[@B35]\]

  Ergyphilus (Nutergia, Capdenac, France)                                     Predominantly *Lactobacillus rhamnosus*GG, but also *L. casei*, *L. acidophilus*and *B. bifidum*                                                                                                                                                                                          One capsule contains 2 × 10^10^lyophilised bacteria. Capsules can be broken and given via enteral feeding tube. Five capsules administered over 24 hours in critically ill patients \[[@B53]\]

  Mutaflor (Ardeypharm GmbH, Herdecke, Germany)                               *Escherichia coli*Nissle 1917                                                                                                                                                                                                                                                             2.5×10^9^to 25×10^9^bacteria per capsule. Adult dose 1 or 2 capsules per day \[[@B97]\]

  Proviva\                                                                    *Lactobacillus plantarum*299v and oatmeal                                                                                                                                                                                                                                                 Oatmeal-based drink containing 5×10^7^CFU/ml. Dose of 500 ml used by McNaught and colleagues \[[@B24]\]
  (Skanemejerier, Malmo, Sweden)                                                                                                                                                                                                                                                                                                                                        

  Synbiotic 2000 (Medipharm, Kagerod, Sweden and Des Moines, IA, USA)         A probiotic mixture comprising *Pediacoccus pentosaceus*5-33:3, *Leuconostoc mesenteroides*77:1, *Lactobacillus paracasei*ssp., paracasei F19, *L. plantarum*2362 plus β-glucan, inulin, pectin and resistant starch                                                                      Administered twice daily via feeding tube or orally \[[@B32]\]

  Synbiotic 2000 Forte (Medipharm, Kagerod, Sweden and Des Moines, IA, USA)   A probiotic mixture comprising *P. pentosaceus*5-33:3, *L. mesenteroides*32-77:1, *L. paracasei*ssp. paracasei 19 and *L. plantarum*2362, plus inulin, oat bran, pectin and resistant starch                                                                                              Sachet for reconstitution containing 10^10^each bacteria plus 10 g prebiotic fibre. Administered in doses of 12 g (1 sachet) per day for a 15-day study period \[[@B47]\]

  Trevis (Christen Hansen, Hørsholm, Denmark)                                 *L. acidophilus*La5*, Lactobacillus bulgaricus*, *B. lactis*Bb-12 and *Streptococcus thermophiles*                                                                                                                                                                                        4×10^9^CFU/capsule. One capsule three times daily \[[@B25],[@B26]\]

  VSL\#3 (Ferring Pharmaceuticals, West Drayton, UK)                          Four strains of *Lactobacillus*(*L. acidophilus*, *L. casei*, *L. plantarum*, *Lactobacillus delbrueckii*), three strains of *Bifidobacterium*(*B. infantis*, *Bifidobacterium longum*, *Bifidobacterium breve*) and one strain of *Streptococcus salivarius*subsp. *Thermophilus*        Powder for reconstitution with water or to be mixed with cold foods prior to consumption. One sachet contains 4.5×10^11^lactic acid bacteria. Also available as a capsule containing 2.25×10^11^bacteria

                                                                                                                                                                                                                                                                                                                                                                        Adult dose 0.5 to 8 sachets (2 to 32 capsules) per day depending upon disease activity. Six grams once a day for 12 months administered by Venturi and colleagues \[[@B13]\]
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CFU, colony-forming units.

Probiotics may alter the local environment within the lumen of the gut, producing antimicrobial effects on pathogenic organisms. Lactic acid-producing and acetic acid-producing probiotics reduce the luminal pH resulting in an unfavourable milieu for pathogens. This has been demonstrated *in vitro*with pathogen growth being reduced in a pH-dependent manner by *Lactobacillus*spp. \[[@B12]\]. Venturi and colleagues demonstrated a significant reduction of luminal pH *in vivo*in ulcerative colitis patients treated with the probiotic mixture VSL\#3 \[[@B13]\].

Probiotics also exert a direct antimicrobial effect via the production of bacteriocins. Bacteriocins are proteins produced by bacteria that inhibit the growth and virulence of other pathogenic bacteria. Probiotic bacteria deficient in the bacteriocin gene are less effective probiotics, as demonstrated in a murine model where a mutant form of *Lactobacillus salivarius*UCC118 failed to protect against infection with *Listeria monocytogenes*\[[@B14]\]. A wide variety of bacteriocins is recognised, and their spectrum of action ranges from antagonism of similar bacterial strains to the inhibition of a wide range of Gram-positives, Gram-negatives, yeasts and moulds \[[@B15]\]. One such example of a broad-spectrum bacteriocin is that produced by a subspecies of *L. salivarius*. The ABP-118 bacteriocin inhibits *Bacillus*, *Staphylococcus*, *Enterococcus*, *Listeria*and *Salmonella*spp. \[[@B16]\].

Bacteria communicate with each other using a mechanism known as quorum sensing. This involves the production and secretion of signalling molecules known as autoinducers. In their *in vitro*study, Medellin-Peña and colleagues demonstrated that *Lactobacillus acidophilus*La-5 secretes molecules that disrupt this interbacterial communication, reducing expression of virulence-related genes by *Escherichia coli*O157:H7 \[[@B17]\].

Probiotics have also been demonstrated to enhance intestinal barrier function. Intestinal barrier function is complex and its control involves cellular stability at a cytoskeletal and tight junction level, as well as mucus, chloride and water secretion. Probiotics have been shown to exert an effect, *in vitro*and *in vivo*, via these mechanisms \[[@B15]\]. For example, *Lactobacillus plantarum*299v can enhance mucus production and secretion in human intestinal epithelial cells \[[@B18]\]. The probiotic strain *E. coli*Nissle 1917 appears to enhance mucosal barrier function by production of human β-defensin 2 \[[@B15]\]. *E. coli*Nissle has also has been demonstrated *in vitro*to reduce adhesion and invasion of intestinal epithelial cells by an enteroinvasive *E. coli*.

In addition, by competing with pathogens for nutrients and adhesion in a microbiological niche, probiotics can prevent replication by pathogens, a phenomenon known as colonisation resistance \[[@B5]\]. Probiotics can thus promote the integrity of the gut defence barrier and create an unfavourable environment for pathogen colonisation.

Probiotics can also exert a range of immunological effects. The interaction between the luminal bacteria and the underlying epithelial and mucosal lymphoid cells is referred to as bacterial-epithelial cross-talk. This crosstalk enables probiotics to have an effect on both the innate and adaptive host immune system \[[@B19]\] - for example, promotion of B cells into plasma cells, increased production of secretory immunoglobulin A and prevention of activation of the proinflammatory nuclear transcription factor NF-κB \[[@B5]\]. Other immunologic mechanisms include alteration of the cytokine profile and activation of macrophages to present antigen to B lymphocytes and increase immunoglobulin production \[[@B20]\].

Probiotics in the critically ill
================================

The efficiency of intestinal barrier function is demonstrated by the fact that the faecal bacterial concentration approaches 10^12^organisms/ml in the caecum, while tissues one cell deep to the intact intestinal mucosa are usually sterile \[[@B21]\]. Any significant insult to the gut or alteration to its microbiota is likely to play a role in promoting systemic inflammation and infection in the critically ill population \[[@B22]\]. In contrast to the large bowel, the stomach, duodenum and jejunum have a relative paucity of bacteria (10^3^to 10^4^organisms/ml). The presence of enteric organisms in gastric aspirates is therefore abnormal and represents gastric colonisation. In the context of critical illness, this colonisation is the result of bacterial overgrowth in the proximal gastrointestinal tract \[[@B21]\].

Colonisation of the stomach by pathogens or potential pathogens is believed to occur due to a combination of poor gut motility, increased gastric pH (due to acid suppression) and the use of broad-spectrum antibiotics. This combination of factors leads to an overgrowth of bacteria in the duodenum, which reflux into the stomach and are ultimately regurgitated and aspirated into the lungs \[[@B23]\].

The normal intestinal microbiota of critically ill patients is altered and replaced by pathogens for a number of reasons. Therefore, it would seem logical to consider that probiotics may have a role in reducing intestinal colonisation by pathogens and thus in the prevention of infection and sepsis syndromes in this population.

Probiotics in the prevention of nonrespiratory infection
========================================================

Probiotics have been studied in the prevention of postoperative infection. Three studies in patients undergoing major colorectal surgery have shown no significant reduction in postoperative infection rates \[[@B24]-[@B26]\]. In each study, however, the effectiveness may have been limited by a relatively short postoperative period of probiotic administration (4 to 5 days). In contrast, several studies in patients undergoing pancreatic resection \[[@B27],[@B28]\] and hepatic resection \[[@B29],[@B30]\] have shown significant reductions in postoperative infection rates of up to 30%. These patients received probiotic for 8 to 14 days post operatively.

Liver transplant patients have multiple risk factors for infection, including profound immunosuppression. Two randomised trials have shown probiotics to be safe and effective in this group of patients. In the first study 95 patients were randomised to receive standard enteral feed plus selective bowel decontamination, fibre-containing enteral feed plus live *L. plantarum*299 (Lp299) or fibre-containing enteral feed plus heat-killed Lp299 \[[@B31]\]. The live Lp299 group developed significantly fewer infections than the other two groups (48% vs. 13% vs. 34%, respectively). In addition, the mean duration of antibiotic therapy, the mean total hospital stay and the length of ICU stay were also shorter than in the groups with inactivated Lp299 and selective bowel decontamination. However, these differences did not reach statistical significance. The second study compared only Synbiotic 2000 and prebiotic fibre, reporting postoperative infection rates of 3% and 48%, respectively \[[@B32]\]. No serious side effects or infections caused by the probiotics were noted in either study.

Oláh and colleagues randomised 45 patients with severe acute pancreatitis to receive enteral oat fibre and live Lp299 or enteral oat fibre and heat-killed Lp299 \[[@B33]\]. In the group treated with the live probiotic, only one patient required surgery for a septic complication involving the pancreas, compared with seven such complications in the control group (*P*= 0.02). There was also a nonsignificant trend toward a shorter length of hospital stay (13.7 days vs. 21.4 days, respectively). The same group carried out a single-centre, double-blind, randomised placebo-controlled trial using Synbiotic 2000 in a further 62 patients with severe acute pancreatitis \[[@B34]\]. This trial showed no statistically significant differences in the incidence of mortality, septic complications or development of multiorgan failure between the two groups. However, the total incidence of systemic inflammatory response syndrome, multiple organ failure and rate of complications was significantly less in the treatment group versus the control group (8 vs. 14, *P*\<0.05 and *P*\<0.05, respectively).

The trial that has raised most concern with regard to adverse outcomes and the use of probiotics is the PROPATRIA trial \[[@B35]\]. In this multicentre, placebocontrolled trial, 296 patients with predicted severe acute pancreatitis were randomised to receive the synbiotic preparation Ecologic 641 or placebo. This was administered together with fibre-enriched enteral feed via the nasojejunal route for 28 days. The rate of infectious complications was similar in both groups (30% vs. 28%) but the mortality rate was higher in the synbiotic group. Nine patients in the synbiotic group developed bowel ischaemia, eight of these being small bowel ischaemia. There were no cases of bowel ischaemia in the placebo group. One possible explanation for this outcome is a difference in the two groups, with more patients in the synbiotic group having established organ failure at the time treatment began. Another theory is that such a significant intestinal burden of bacteria and high-fibre feed could result in increased oxygen consumption and local bowel ischaemia. Nevertheless, this is the first time such a complication has been reported.

Probiotics in the prevention of respiratory infection
=====================================================

The respiratory tract is consistently the most common site of nosocomial infection, accounting for 65% of ICU-acquired infections \[[@B36]\]. Ventilator-associated pneu monia (VAP) complicates the care of up to 30% of patients receiving mechanical ventilation, accounting for 50 to 60% of total antibiotic days \[[@B37]-[@B40]\]. Patients with VAP present increased morbidity and mortality, prolonged ICU and hospital lengths of stay, and increased costs \[[@B41]\].

Current VAP prevention strategies aim to reduce colonisation of the oropharynx and upper gastrointestinal tract with pathogenic bacteria and prevent their subsequent aspiration. These measures include elevation of the head of the bed, silver-coated tracheal tubes, oral care, subglottic secretion drainage and use of sedation breaks and weaning protocols. Selective digestive tract decontamination using antibiotics in the oral cavity or whole gastrointestinal tract decontamination have been shown to reduce rates of VAP and mortality \[[@B42],[@B43]\]. However, these strategies have not gained widespread favour in critical care owing to concerns about promoting antibiotic resistance. Oostdijk\'s group demonstrated a statistically significant increase in intestinal colonisation with Gram-negative bacteria resistant to ceftazidime, tobramycin or ciprofloxacin (*P*\<0.05) \[[@B44]\]. These concerns were also borne out by a large-cluster, randomised cross-over study of selective decontamination of the digestive tract that showed a marked increase resistance to ceftazidime in faecal *Enterobacteriaceae*, together with a small but significant increase in bacterial resistance from the respiratory tract \[[@B45]\]. In a previous study, the use of cefotaxime as part of selective decontamination of the digestive tract regime was found to select for an outbreak of extended-spectrum β-lactamase-producing *E. coli*and *Klebsiella pneumonia*\[[@B46]\].

To date there have been eight randomised controlled trials of probiotic therapy as a strategy to prevent VAP \[[@B38],[@B47]-[@B53]\]. The inclusion criteria, sample size (range 50 to 348), populations studied and diagnostic criteria for VAP varied between studies. The probiotic formula, dosing and route of administration also varied but all trials contained *Lactobacillus*spp. (see Table [3](#T3){ref-type="table"}). Six of the eight trials showed a lower incidence of VAP in the probiotic group \[[@B38],[@B47],[@B48],[@B50]-[@B52]\], but this difference was statistically significant in only three of the studies \[[@B38],[@B47],[@B48]\]. Interestingly, one study used chlorhexidine oral disinfection as a control and found that probiotic Lp299 was at least as effective in preventing oropharyngeal colonisation (61.9% vs. 34.8% new colonisation, respectively; *P*= 0.13) \[[@B50]\]. The study by Forestier and colleagues found no difference in incidence of VAP between groups but did demonstrate a median delay in respiratory colonisation with *Pseudomonas aeruginosa*of 50 days versus 11 days in controls (*P*= 0.01) \[[@B49]\]. This is the most commonly isolated antibiotic-resistant Gramnegative species in VAP \[[@B39]\].

###### 

Probiotic trials in mechanically ventilated patients for prevention of ventilator-associated pneumonia/respiratory tract infection

  Study                                                      *n*   Study design                         Study population                                                                                     Probiotic regimen                                                                                                                                 Primary endpoint                                                                                                                                                                  Additional findings                                                                                                                                                                                                                                                                                                                                                                                   Limitations
  ---------------------------------------------------------- ----- ------------------------------------ ---------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **VAP/respiratory tract infection as primary outcome**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Forestier and colleagues \[[@B49]\]                        208   DB, SC, RCT                          Mixed ICU, \>18 years old, requiring MV \>48 hours                                                   *Lactobacillus casei rhamnosus*, 10^9^CFU vs. placebo ng/og twice daily until ICU discharge or death                                              Time to first colonisation/infection of the gastric and respiratory tracts with *Pseudomonas aeruginosa*strains. Median delay 50 days probiotic vs. 11 days placebo (*P*= 0.01)   *P. aeruginosa*VAP reduced in probiotic group: 2.9% vs. 7.5% (*P*= NS). No adverse effects                                                                                                                                                                                                                                                                                                            Single centre. More patients in probiotic group than placebo received antipseudomonal antibiotics during their admission (55% vs. 43%)
  Knight and colleagues \[[@B51]\]                           259   DB, SC, RCT                          Mixed ICU, \>16 years old, requiring MV \>2 days                                                     Synbiotic 2000 Forte: 10^10^CFU vs. placebo ng/og twice daily until day 28, ICU discharge or death                                                Incidence of VAP: 9% probiotic vs. 13% placebo (*P*= 0.42)                                                                                                                        Hospital mortality: 27% vs. 33% (*P*= 0.39). No adverse effects                                                                                                                                                                                                                                                                                                                                       Single centre. Overall VAP rate lower than anticipated
  Morrow and colleagues \[[@B38]\]                           146   DB, SC, RCT                          Mixed ICU, \>18 years old, expected to require MV \>72 hours                                         *Lactobacillus rhamnosus*GG 10^9^CFU vs. placebo per orally and ng twice daily, started within 24 hours until death, extubation or tracheostomy   Incidence of VAP: 19.1% probiotic vs. 40% placebo (*P*= 0.007)                                                                                                                    Significant reduction in *Clostridium* difficile-*associated* diarrhoea and ICU-associated diarrhoea, fewer antibiotic days, delay in onset of VAP, reduction in gastric and oral colonisation with pathogenic species, preferential reduction in VAP caused by Gram-negative pathogens. No adverse effects                                                                                           Single centre. Small sample size. High-risk population, selected: mean APACHE II score 23, mean days ventilated 10 days. Extensive exclusions: pregnancy; immunosuppression; prosthetic heart valve or vascular graft; cardiac trauma; history of rheumatic fever, endocarditis or congenital heart defect; gastro-oesophageal or intestinal injury or foregut surgery; oropharyngeal injury; tracheostomy
  **VAP/respiratory tract infection as secondary outcome**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Kotzampassi and colleagues \[[@B47]\]                      65    DB, two centre, RCT                  Severe multiple trauma patients, \>18 years old, requiring MV                                        Synbiotic 2000 Forte: 10^11^CFU vs. placebo once daily via gastrostomy or ng for 15 days                                                          Systemic infection rate during ICU stay or the development of SIRS and MODS. Overall infection rate: 63% probiotic vs. 90% placebo (*P*= 0.01)                                    VAP rate reduced in probiotic group: 54% vs. 80% in placebo group (*P*= 0.03). Central line and urinary tract infections also significantly reduced. Severe sepsis: 17% vs. 40% (*P*= 0.04). Ventilation days (*P*= 0.001) and ICU length of stay (*P*= 0.01) significantly reduced with probiotics. Reduction in mortality (14.3% vs. 30%) nonsignificant (*P*= 0.12). No adverse effects            Small sample size, severe trauma patients only
  Spindler-Vessel and colleagues \[[@B48]\]                  132   SC, RCT                              Severe multipletrauma patients requiring MV, at least 4-day ICU stay                                 Synbiotic 2000 Forte, 10^10^CFU vs. glutamine or fermentable fibre or peptide diet once daily ng/og for 15 days or until ICU discharge or death   Effect on intestinal permeability reduced on day 7 in probiotic group only (*P*\<0.05)                                                                                            Probiotic group also had fewer pneumonias (*P*= 0.03) and total infections (*P*= 0.003). No adverse effects                                                                                                                                                                                                                                                                                           Single centre. Small sample size, comparing multiple interventions, no placebo group
  Klarin and colleagues \[[@B50]\]                           50    Open label, SC, RCT                  Mixed ICU, 18 years old, requiring MV \>24 hours                                                     *Lactobacillus plantarum*299, 10^10^CFU vs. 0.1% chlorhexidine per orally twice daily until ICU discharge or death                                Pathogenic bacterial load in oropharynx. New colonisation rate: 34.8% probiotic vs. 61.9% chlorhexidine (*P*= 0.13)                                                               Emerging bacteria largely Gram-negative species. Noncolonised patients had lower ventilator days (*P*\<0.001). Incidence of VAP: 4% probiotic group vs. 14% chlorhexidine group (*P*= NS). No adverse effects                                                                                                                                                                                         Single centre. Not powered for incidence of VAP as primary outcome. Small sample size
  Barraud and colleagues \[[@B53]\]                          167   DB, SC, RCT                          Medical ICU, \>18 years old, MV \> 48 hours                                                          Ergyphilus 2×10^10^lactic acid bacteria, mostly *L. rhamnosus*GG, once a day vs. placebo via enteral feeding tube.                                28-day mortality. No difference: 25.3% probiotic vs. 23.7% placebo (*P*= 0.8)                                                                                                     Mortality rates in ICU and at 90 days were also unaffected by the treatment. Incidence of ICU-acquired infections including VAP not significantly different except for catheter-related bloodstream infections that were lowered by probiotics. Reduced 28-day mortality in severe sepsis patients given probiotics (*P*= 0.035) but higher mortality rate in nonsevere sepsis patients (*P*= 0.08)   Single centre. Small sample. Stopped early
  Oudhuis and colleagues \[[@B52]\]                          254   Two centre, open label, cross over   Mixed ICUs, consecutive ICU patients with expected MV ≥48 hours and/or expected ICU stay ≥72 hours   *L. plantarum*299/299v in a dose of 5×10^9^CFU together with 6 g of rose-hip, twice daily via ng vs. SDD                                          ICU-acquired infection rate: 31% probiotic vs. 24% SDD (*P*= 0.10)                                                                                                                No significant difference in VAP rate (7.7% vs. 7.2%.), 28-day or ICU mortality between groups                                                                                                                                                                                                                                                                                                        Small sample size. Stopped early. Crossover of units was not completed, resulting in unequal mix of patients and disease burden. Not DB. Infections defined retrospectively

APACHE, Acute Physiology and Chronic Health Evaluation; CFU, colony-forming units; DB, double blind; MODS, multiorgan dysfunction syndrome; MV, mechanical ventilation; ng, nasogastric; NS, not significant; og, orogastric; RCT, randomised controlled trial; SC, single centre; SDD, selective decontamination of digestive tract; SIRS, systemic inflammatory response syndrome; VAP, ventilator-associated pneumonia.

Conflicting results also arise from meta-analyses of probiotics in critical care. The work by Watkinson and colleagues in 2007 analysed the use of prebiotics, probiotics and synbiotics in 999 adult critical care patients from eight randomised controlled trials and concluded that there was no benefit in the probiotic prophylaxis of VAP \[[@B54]\]. In 2010, however, Siempos and colleagues examined five randomised controlled trials (689 patients) and showed that probiotic administration was associated with a lower incidence of VAP when compared with standard care (odds ratio = 0.61; 95% confidence interval = 0.31 to 0.91) \[[@B55]\]. Importantly, both of these were published before the studies by Morrow and colleagues \[[@B38]\], Oudhuis and colleagues \[[@B52]\] and Barraud and colleagues \[[@B52]\].

The trial by Morrow and colleagues is unique in that it included oropharyngeal slurry as one of the routes of administration for the probiotic \[[@B38]\]. The research group randomised 146 ventilated patients who were considered at high risk for VAP to receive probiotic *L. rhamnosus*GG or placebo (inulin) within 24 hours of intubation until extubation, tracheostomy or death. The primary outcome was microbiologically confirmed VAP based on quantitative culture of distal airway samples obtained by bronchoscopy. The incidence of VAP was significantly reduced in the probiotic group (19.1% with probiotic vs. 40.0% with placebo, *P*= 0.007).

Morrow and colleagues also examined the incidence of *Clostridium difficile*and ICU-associated diarrhoea in their patients. The probiotic group had significantly less *C. difficile*cytotoxin-positive diarrhoea compared with the placebo group (5.6% vs. 18.6%, *P*= 0.02), although the duration of diarrhoea was not significantly lower. However, patients treated with probiotic received fewer days of antibiotics for *C. difficile*-associated diarrhoea (0.5 ± 2.3 days vs. 2.1 ± 4.8 days in placebo group, *P*= 0.02). The duration of ICU-associated diarrhoea was also significantly reduced in the probiotic group (4.1 ± 3.7 days vs. 5.9 ± 3.8 days in placebo group, *P*= 0.03).

The rates of oral colonisation with pathogenic species at 72 hours (70% for placebo vs. 38.2% for *Lactobacillus*, *P*\<0.001) correlated with development of VAP (Pearson correlation coefficient = 0.22, *P*= 0.009). Interestingly, the probiotic treatment appeared to preferentially reduce rates of infection caused by Gram-negative pathogens (22.8% for placebo vs. 8.8% for *Lactobacillus*, *P*= 0.02) while having no statistically significant effect on Grampositive species (12.8% vs. 5.8%, *P*= 0.16).

To date, studies of probiotics in the critically ill have trialled a number of species, *Lactobacillus*featuring frequently. Currently unknown, however, is whether one species is superior in the prevention of infection associated with critical illness. Similarly, the optimal administration route, dosage and duration of treatment are not clear. Further research is undoubtedly warranted, perhaps considering Gram-negative probiotic species.

Administration of probiotics and monitoring of their effects
============================================================

Probiotics are commercially available in various preparations including yoghurt-based products, capsules, powders and suspensions. The studies in critically ill patients discussed above involve enteral administration of a variety of probiotic strains using different dosing regimes.

In eight of the nine studies involving mechanically ventilated patients (Table [3](#T3){ref-type="table"}), probiotic powder or capsule contents were dissolved in water and delivered via a feeding tube into the stomach. Morrow and colleagues used an oropharyngeal slurry of *L. rhamnosus*GG (suspended in a sterile water-based surgical lubricant) in addition to nasogastric administration \[[@B38]\]. After 72 hours, the patients receiving this regime were found to have lower rates of oral (38.2% vs. 70%, *P*= 0.001) and gastric (32.3% vs. 45.7%, *P*= 0.03) colonisation with pathogenic species than those receiving placebo. Klarin and colleagues used topical application of Lp299 to the oral cavity alone and found it to be at least as effective as chlorhexidine 0.1% in reducing oropharyngeal pathogenic load \[[@B50]\].

Testing for colonisation of the gastrointestinal tract with the probiotic species is reported in only a minority of studies. McNaught and colleagues collected gastric aspirates at induction of anaesthesia in elective surgical patients who had received at least 1 week of oral Lp299 \[[@B24]\]. The probiotic species was not isolated in any subject. In the study by Forestier and colleagues, however, gastric aspirates were taken at inclusion, at day 7 and at discharge. *Lactobacillus casei rhamnosus*was detected in 52 out of 102 patients on probiotic treatment after a median of 13 days \[[@B49]\]. In the study by Klarin and colleagues described above, the probiotic species Lp299 was detected in all oropharyngeal cultures and in the tracheal cultures from 56% of patients in the probiotic arm \[[@B50]\]. Knight and colleagues demonstrated detection of probiotic species in stool culture after 3 days treatment with Synbiotic 2000 Forte, indicating its survival from the stomach to the distal gut \[[@B56]\]. However, they did not routinely analyse stool samples in their more recent study \[[@B51]\]. None of the other studies cited in Table [3](#T3){ref-type="table"} reported detection of probiotic species in any microbiological specimens.

Quality and safety
==================

Probiotics are now widely available and are being consumed daily in large quantities. Overall they have an excellent safety record, but there are some concerns that are likely to lead to caution in their widespread use in clinical practice.

The availability of different probiotics varies from country to country and there can be lack of consistency between manufacturers, and even batches, in terms of density of bacteria, adhesion characteristics, stability and viability \[[@B57]\]. Strain-specific adhesion properties and viability have been shown to vary between batches from the same manufacturer, which could lead to conflicting clinical trial results \[[@B58]\].

There have been a number of publications reporting serious infections caused by *Lactobacillus*spp. related to those used as probiotics \[[@B59]\]. The Finnish group of Salminen and colleagues examined 89 cases of *Lactobacillus*bacteraemia. In 11 cases, the strain was identical with the probiotic *L. rhamnosus*GG \[[@B60]\]. However, they could not directly relate these cases to probiotic consumption. Salminen and colleagues also examined trends in *Lactobacillus*bacteraemia in Finland over the period 1990 to 2000. This period coincided with a rapid increase in the consumption of probiotic *L. rhamnosus*GG. The group concluded that increased probiotic use had not led to an increase in *Lactobacillus*bacteraemia \[[@B61]\].

There are case reports in the literature of *Lactobacillus*infection and bacteraemia that appear to be directly related to probiotic consumption \[[@B62]-[@B65]\]. All of the patients involved were immunocompromised to some degree and the causative organism was linked to the probiotic by molecular techniques. Infections caused by *Lactobacillus*spp. from probiotics have also been reported in immunosuppressed patients - including those with acquired immunodeficiency syndrome and those following lung and liver transplantation \[[@B66]-[@B68]\]. *Lactobacillus*bacteraemia has been associated with structural heart abnormalities, valve prosthesis or prior endocarditis \[[@B69]\]. However, the majority of clinical trials using *Lactobacillus*spp. probiotics report few adverse effects.

The only reported infection associated with probiotic *E. coli*Nissle 1917 is in a premature neonate (gestational age 28 weeks) \[[@B70]\]. The child had an extremely low birth weight of 935 g and developed gastroenteritis due to rotavirus and adenovirus 14 days into the postnatal period. *E. coli*Nissle treatment initially led to improvement but the child developed severe sepsis 10 days later and subsequently *E. coli*Nissle 1917 was isolated in blood cultures. The child was treated with antibiotics and made a full recovery.

A wide range of probiotic species is being investigated for an increasing number of indications. There has been little work carried out on the rationale behind which probiotics are used and in what combination. Timmerman and colleagues attempted to address this issue by examining specific strains in an attempt to produce an effective multispecies mixture \[[@B71]\]. The symbiotic preparation Ecologic 641 was used in the PROPATRIA trial. This group selected six strains of *Lactobacillus*based on survival in a simulated gastrointestinal environment, antimicrobial activity and ability to induce IL-10, highlighting the point that there should be a disease-specific rationale for selection of probiotics.

Conclusions
===========

Concerns are mounting about multidrug-resistant Gram-negative bacteria with the extensive spread of extended-spectrum β-lactamases \[[@B72]\], and in particular the emergence of *Enterobacteriaceae*with resistance to carbapenems conferred by metallo-β-lactamase NDM-1 \[[@B73]\]. New antimicrobial agents with which to tackle resistant bacteria are in limited supply, and a recently announced EU-US taskforce has called for a commitment to the development of 10 new antibacterial agents by 2020. This will require a substantial public financial investment and will need to be sustained long term because continued antibiotic use will maintain the pressure on organisms to evolve new resistant strains. In the absence of universally effective treatments, strategies that could prevent the development of ICU-acquired infection are needed.

The human, animal and *in vitro*studies of probiotics carried out to date exhibit a high level of heterogeneity in the conditions targeted, models used and probiotics tested. These studies are likely to reflect an oversimplistic view of the mechanisms of action of probiotic species. As alluded to above, probiotics are likely to bring about their effects through multiple processes with different strains having very specific effects.

We are still far from understanding fully the probiotic-host interaction but, given the potential benefits that probiotic bacteria have to offer, further study is warranted. Careful consideration should be given to further well-powered studies addressing the questions of which probiotic by what route, in what dose and at what time.
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